UNICYCIVE THERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $348.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-12
- UNICYCIVE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $145.00K, a 9.85% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $203.00K, a 59.84% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $141.00K, a 11.02% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $138.00K, a 17.95% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $538.00K, a 32.51% increase from fiscal 2024.
- UNICYCIVE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $406.00K, a 47.64% increase from fiscal 2023.
- UNICYCIVE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $275.00K, a 78.57% increase from fiscal 2022.
- UNICYCIVE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $154.00K, a 1183.33% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $145.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $348.00K 10-Q · filed 2026-08-12 | $489.00K derived: sum of 3 quarters · filed 2026-08-12 | $627.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $203.00K 10-Q · filed 2026-05-12 | $344.00K derived: sum of 2 quarters · filed 2026-05-12 | $482.00K derived: sum of 3 quarters · filed 2026-05-12 | $614.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $279.00K derived: sum of 2 quarters · filed 2026-03-30 | $411.00K derived: sum of 3 quarters · filed 2026-08-12 | $538.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $138.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $270.00K derived: sum of 2 quarters · filed 2026-08-12 | $397.00K 10-Q · filed 2025-11-12 | $524.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $132.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $259.00K 10-Q · filed 2026-08-12 | $386.00K derived: sum of 3 quarters · filed 2026-08-12 | $503.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $127.00K 10-Q · filed 2026-05-12 | $254.00K derived: sum of 2 quarters · filed 2026-05-12 | $371.00K derived: sum of 3 quarters · filed 2026-05-12 | $258.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $244.00K derived: sum of 2 quarters · filed 2026-03-30 | $131.00K derived: sum of 3 quarters · filed 2026-03-30 | $406.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $117.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.00K derived: sum of 2 quarters · filed 2025-11-12 | $279.00K 10-Q · filed 2025-11-12 | $358.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $162.00K 10-Q · filed 2025-08-14 | $241.00K derived: sum of 3 quarters · filed 2025-08-14 | $318.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $275.00K 10-Q · filed 2025-05-14 | $354.00K derived: sum of 2 quarters · filed 2025-05-14 | $431.00K derived: sum of 3 quarters · filed 2025-05-14 | $507.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $156.00K derived: sum of 2 quarters · filed 2025-03-31 | $232.00K derived: sum of 3 quarters · filed 2025-03-31 | $275.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $153.00K derived: sum of 2 quarters · filed 2024-11-13 | $196.00K 10-Q · filed 2024-11-13 | $236.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $76.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $119.00K 10-Q · filed 2024-08-14 | $159.00K derived: sum of 3 quarters · filed 2024-08-14 | $198.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $43.00K 10-Q · filed 2024-05-13 | $83.00K derived: sum of 2 quarters · filed 2024-05-13 | $122.00K derived: sum of 3 quarters · filed 2024-05-13 | $160.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $79.00K derived: sum of 2 quarters · filed 2024-03-28 | $117.00K derived: sum of 3 quarters · filed 2024-03-28 | $154.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $77.00K derived: sum of 2 quarters · filed 2023-11-14 | $114.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $75.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $37.00K 10-Q · filed 2023-05-16 | |||
| 2021-12-31 | $12.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |